Patents by Inventor Cheryl Fitzer-Attas
Cheryl Fitzer-Attas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9308182Abstract: This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally administering to the subject a controlled release formulation comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 16, 2013Date of Patent: April 12, 2016Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Cheryl Fitzer-Attas, Rom E Eliaz, Eran Blaugrund, Aviva Gross, Adi Mayk
-
Publication number: 20150216850Abstract: This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease, comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder. This invention further provides use of rasagiline and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder.Type: ApplicationFiled: September 27, 2013Publication date: August 6, 2015Inventors: Michael HAYDEN, Cheryl FITZER-ATTAS
-
Publication number: 20140088145Abstract: This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease, comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder. This invention further provides use of rasagiline and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder.Type: ApplicationFiled: September 27, 2013Publication date: March 27, 2014Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Michael Hayden, Cheryl Fitzer-Attas
-
Publication number: 20140051767Abstract: This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally administering to the subject a controlled release formulation comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 16, 2013Publication date: February 20, 2014Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Cheryl Fitzer-Attas, Rom E. Eliaz, Eran Blaugrund, Aviva Gross, Adi Mayk
-
Patent number: 7960507Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: July 27, 2010Date of Patent: June 14, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas, Arthur Machlenkin, Esther Tzehoval
-
Publication number: 20100291127Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: July 27, 2010Publication date: November 18, 2010Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: LEA EISENBACH, BOAZ TIROSH, EREZ BAR-HAIM, ADRIAN PAZ, MATITYAHU FRIDKIN, CHERYL FITZER-ATTAS, ARTHUR MACHLENKIN, ESTHER TZEHOVAL
-
Patent number: 7795224Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: December 2, 2008Date of Patent: September 14, 2010Assignee: Yeda Research and Development Co., Ltd.Inventors: Lea Eisenbach, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Publication number: 20090136462Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: December 2, 2008Publication date: May 28, 2009Applicant: YEDA RESEARCH AND DEVELOPMENT CO. Ltd.Inventors: Lea EISENBACH, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Publication number: 20090062400Abstract: Disclosed is a method of reducing glaucoma in a subject afflicted with glaucoma, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to reduce glaucoma.Type: ApplicationFiled: September 3, 2008Publication date: March 5, 2009Inventors: Laurence Oron, Cheryl Fitzer-Attas, Ron Neumann
-
Publication number: 20060194730Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: ApplicationFiled: March 29, 2006Publication date: August 31, 2006Applicant: YEDA RESEARCH AND DEVELOPMENT CO. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Patent number: 7084249Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.Type: GrantFiled: July 29, 1999Date of Patent: August 1, 2006Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Lior Carmon, Boaz Tirosh, Erez Bar-Haim, Adrian Paz, Matityahu Fridkin, Cheryl Fitzer-Attas
-
Publication number: 20040091945Abstract: The invention is in the field of immunogenicity. In one embodiment, the invention relates to method of identifying T-cell epitopes in amyloid beta peptide or homologue thereof. In another embodiment, the invention relates to a vaccine comprising an amyloid beta peptide or homologue thereof, whereby the selected peptide is a peptide which lacks certain T-cell epitopes or a peptide which is modified by deleting or modifying amino acids so as to reduce or eliminate the T-cell epitopes. The selected peptides are further assessed for reduced capacity to form fibrils, reduced cytotoxicity, and a reduced ability to induce a cellular autoimmune response. The selected peptides are further assessed for ability to induce a humoral immune response. In another embodiment, the invention relates to a method of predicting the reaction of an individual to a vaccine, which comprises amyloid beta peptide or homologue thereof, based on the HLA haplotype of the subject.Type: ApplicationFiled: July 16, 2003Publication date: May 13, 2004Inventors: Cheryl Fitzer-Attas, Daniel G. Chain